Tirzepatide Injection

Buy Tirzepatide Injection Online

Tirzepatide is a first-in-class dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. By targeting both receptor pathways, tirzepatide helps lower blood sugar levels, improve insulin sensitivity, slow gastric emptying, and support substantial weight management when combined with a reduced-calorie diet and increased physical activity.

Indications & Usage

• Type 2 Diabetes Mellitus: Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

• Chronic Weight Management: Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of:

  • $\ge 30 \text{ kg/m}^2$ (obesity) or

  • $\ge 27 \text{ kg/m}^2$ (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea).

How It Works (Mechanism of Action)

Unlike traditional single-target GLP-1 medications, tirzepatide works by mimicking two natural gut hormones:

1. GIP Receptor Activation: Enhances glucose-dependent insulin secretion, improves fat metabolism, and works synergistically with GLP-1 to suppress appetite.

2. GLP-1 Receptor Activation: Delays stomach emptying (keeping you full longer), signals satiety to the brain, and decreases glucagon secretion to prevent unwanted liver glucose release.

Dosage & Administration

Tirzepatide is administered once weekly via subcutaneous injection into the abdomen, thigh, or upper arm at any time of day, with or without food.

Important Safety Information & Precautions

Boxed Warning: Risk of Thyroid C-Cell Tumors

In animal studies, tirzepatide caused thyroid C-cell tumors. It is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Contraindications

• Known hypersensitivity to tirzepatide or any of its inactive ingredients.

• Personal or family history of Medullary Thyroid Carcinoma (MTC).

• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Key Warnings

• Pancreatitis: Discontinue immediately if pancreatitis is suspected.

• Hypoglycemia Risk: Increased when used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin.

• Severe Gastrointestinal Disease: Not recommended in patients with severe gastrointestinal disease, including severe gastroparesis.

• Acute Kidney Injury: Gastrointestinal adverse reactions associated with dehydration may cause renal failure.

• Gallbladder Disease: Monitor for signs of cholelithiasis or cholecystitis.

Common Side Effects

Gastrointestinal reactions are the most common side effects, particularly during the dose-escalation phase:

• Nausea

• Diarrhea

• Decreased appetite

• Vomiting

• Constipation

• Abdominal pain or indigestion

Storage & Handling

• Refrigeration: Store in a refrigerator between 2°C to 8°C (36°F to 46°F) in the original carton to protect from light.

• Room Temperature: May be stored at room temperature up to 30°C (86°F) for up to 21 days. Do not return to the refrigerator after storing at room temperature.

• Do Not Freeze: If the medicine freezes, discard it immediately. Avoid direct heat and sunlight.